By Fineline Cube Bristol-Myers Squibb (BMS) (NYSE: BMY) announced that the US Food and Drug Administration (FDA) has approved iberdomide in combination with subcutaneous daratumumab and dexamethasone (IberDd) for adult patients with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. The decision marks the FDA’s first‑ever approval in the relapsed or refractory multiple myeloma (RRMM) setting based on minimal residual disease (MRD)‑negative complete response data.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (US) |
| Approval Type | Standard approval |
| Product | Iberdomide + subcutaneous daratumumab + dexamethasone (IberDd) |
| Indication | Adult multiple myeloma patients with ≥1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent |
| Announcement Date | 14 Aug 2026 |
| Basis | Phase III EXCALIBER‑RRMM trial; first FDA approval in RRMM anchored on MRD‑negative CR data |
Drug Profile & Mechanism of Action
- Molecule: Iberdomide, a novel Cereblon E3 ligase modulator (CELMoD)
- Class: New generation of targeted protein degradation therapies
- Mechanism: Modulates the cereblon E3 ligase pathway to drive selective degradation of disease‑relevant proteins in multiple myeloma
- Combination Backbone: Paired with subcutaneous daratumumab (anti‑CD38 antibody) and dexamethasone in the approved regimen
Clinical Evidence – Phase III EXCALIBER‑RRMM Trial
| Endpoint | Result (IberDd, n=207) | Comparator (DVd, n=213) | Relative Benefit |
|---|---|---|---|
| MRD‑Negative Complete Response Rate | 41 % (n=85; 95 % CI: 34–48) | 21 % (n=44; 95 % CI: 15–27) | +20 ppt, p < 0.0001 |
| Follow‑Up | Median 16 months | Median 16 months | – |
| Statistical Significance | Met one of the dual primary endpoints | – | Statistically significant |
The trial evaluated iberdomide plus subcutaneous daratumumab and dexamethasone against daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. MRD negativity is a critical metric for evaluating response depth in multiple myeloma and is considered predictive of improved progression‑free survival (PFS).
Market Impact & Outlook
- New Drug Class: Iberdomide’s approval establishes CELMoD agents as a validated mechanism in multiple myeloma, broadening treatment options for patients who relapse after proteasome inhibitors and immunomodulatory agents.
- Regulatory Precedent: By approving on MRD‑negative CR data, the FDA signals that response depth may serve as a meaningful basis for future approvals in RRMM — a potential shift in how myeloma trials are designed and evaluated.
- Portfolio Expansion: The approval strengthens Bristol‑Myers Squibb’s hematology franchise with a differentiated mechanism of action in one of the most common hematologic malignancies.
- Competitive Positioning: IberDd’s head‑to‑head superiority on MRD‑negative CR versus an active daratumumab‑based triplet positions the regimen as a potential new standard for second‑line and later therapy.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical outcomes, regulatory precedent, and market expectations for iberdomide. Actual results may differ due to risks including longer‑term efficacy and safety data, market adoption, and competitive dynamics.-Fineline Info & Tech